Instrumentation for the Coagulation Laboratory

  • Christopher M. LehmanEmail author


A broad spectrum of coagulation analyzers is available for purchase on the market today. Laboratories can choose from manual, semi-automated or fully automated, moderate or high-throughput analyzers with narrow or broad assay menus depending upon clinical and test volume requirements. These laboratory-based instruments require plasma prepared from spun, anticoagulated whole blood for analysis. In addition, a number of point of care (POC) devices designed to analyze fresh whole blood are available for use on hospital patient care units, in clinics and doctors’ offices, and even in patients’ homes. For a current summary of marketed devices, the reader is referred to the annual College of American Pathologists summary list of laboratory-based coagulation analyzers and their attributes published on the College’s web site ( A separate list of point of care analyzers can also be found on the site.


International Normalize Ratio Platelet Function Activate Clotting Time Clot Lysis Platelet Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Moreira PL, Lansden CC, Clark TL. Effect of Hemopure® on prothrombin time and activated partial thromboplastin time on seven coagulation analyzers. Clin Chem. 1997;43:1792.PubMedGoogle Scholar
  2. 2.
    Mischke R, Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis. 2000;30:123–30.PubMedGoogle Scholar
  3. 3.
    Mischke R, Menzel D, Wolling H. Comparison of different methods to measure fibrinogen concentration in canine plasma with respect to their sensitivity towards the fibrinogen degradation products X, Y and D. Haemostasis. 2000;30:131–8.PubMedGoogle Scholar
  4. 4.
    Point-of-care monitoring of anticoagulation therapy; approved guideline. CLSI document H49-A. Wayne: Clinical and Laboratory Standards Institute; 2004.Google Scholar
  5. 5.
    Remijn JA, Wildeboer B, van Suijlen JDE, Adriaansen HJ. Recombinant thromboplastins vs tissue-extract thromboplastins in patients on unstable oral anticoagulant therapy. Clin Chem. 2011;57:916–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Murray ET, Fitzmaurice DA, McCahon D. Point of care testing for INR monitoring; where are we now? BMJ. 2004;127:373–8.Google Scholar
  7. 7.
    Spinler SA, Nutescu EA, Smythe MA. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother. 2005;39:1049–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Yang DT, Robetorye R, Rodgers GM. Home prothrombin time monitoring: a literature analysis. Am J Hematol. 2004;77:177–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Sephel GC, Laposata M. Transiently increased variation between a point-of-care and laboratory INR method after a long period of correlation. Am J Clin Pathol. 2013;140:475–86.PubMedCrossRefGoogle Scholar
  10. 10.
    Dalbert S, Ganter MT, Furrer L. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices. Acta Anesthesiol Scand. 2006;50:461–8.CrossRefGoogle Scholar
  11. 11.
    Santrach PJ. Point-of-care hematology, hemostasis, and thrombolysis testing. In: Kost GJ, editor. Principals and practice of point-of-care testing. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 157–80.Google Scholar
  12. 12.
    Kratz A, Van Cott EM. Activated clotting time methods and clinical applications. Point of Care. 2005;4:90–4.Google Scholar
  13. 13.
    Mylotte D, Foley D, Kenny D. Platelet function testing: methods of assessment and clinical utility. Cardiovasc Hematol Agents Med Chem. 2011;9:14–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Salooja N, Perry DJ. Thromboelastography. Blood Coagul Fibrinolysis. 2001;12:327–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Horlocker TT, Schroeder DR. Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations. Mayo Clin Proc. 1997;72:214–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16:1–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Hayward CPM, Harrison P, Cataneo TL, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312–19.Google Scholar
  18. 18.
    Hayward CPM, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Harrison P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Haubelt H, Anders C, Vogt A, et al. Variables influencing platelet function analyzer-100™ closure times in healthy individuals. Br J Haematol. 2005;130:759–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of PathologyUniversity of Utah Health Sciences CenterSalt Lake CityUSA
  2. 2.Hospital Clinical LaboratoriesARUP LaboratoriesSalt Lake CityUSA

Personalised recommendations